Krystal Biotech Inc. appears to be picking up steam for the year's second half. The company's Vyjuvek topical gel for treating Dystrophic Epidermolysis Bullosa (DEB) was approved by the FDA on May 19, leading to a major funding announcement.
Algernon Pharmaceuticals Inc. has received a U.S. patent for a ground-breaking new Non-Alcoholic Steatohepatitis (NASH) drug under investigation, and is developing another for refractory chronic cough (RCC). Click here to read how the company is repurposing these two treatments with drugs that have a known safety history.
Defense stocks are uniquely positioned to enjoy considerable, reliable funding from government contracts. This stability, and the ensuing profitability, increases during times of international political instability.
Phase 3 trials are the last major step in new drug approval and can cost a lot to operate. However, one Canadian pharma company's product is so promising it has convinced the UK government to foot most of the bill.
Algernon Pharmaceuticals Inc. and its subsidiary Algernon NeuroScience have reached a new milestone in a clinical trial investigating the psychedelic drug DMT for the treatment of brain injuries. Click here to learn more about new applications for psychedelics.
The investigative, novel small molecule is the lead drug candidate for this U.S. biopharma developing treatments for serious oncological conditions of unmet medical need, noted an H.C. Wainwright & Co. report.
The Canadian specialty pharma, with a proven track record of in-licensing and acquiring late-stage assets, is "poised to grow meaningfully in the coming years," noted an Echelon Capital Markets report.